A Phase 1, Single‐Center, Randomized, Double‐Blind, Placebo‐Controlled, Multiple‐Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu‐pGSN) Following Intravenous Administration to Healthy Volunteers
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70094 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Yao Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: BioAegis Therapeutics, North Brunswick, NJ, USA. Hauptthemen laut MEDLINE: Gelsolin, Recombinant Proteins, Anti-Inflammatory Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BioAegis Therapeutics.
Abstract (Originalsprache)
Plasma gelsolin (pGSN) is a non‐immunosuppressive anti‐inflammatory immunomodulator with demonstrated efficacy in animal models of acute lung injury. Its therapeutic potential for moderate‐to‐severe acute respiratory distress syndrome is currently under investigation. This randomized, double‐blind, placebo‐controlled study assessed the safety, pharmacokinetics, and immunogenicity of multiple ascending doses of recombinant human pGSN (rhu‐pGSN) in healthy volunteers. Thirty‐two participants were enrolled across four dose cohorts (6, 12, 18, and 24 mg/kg of body weight), randomized 3:1 to receive five daily intravenous (IV) infusions of rhu‐pGSN or placebo. Plasma pGSN concentrations increased as dose increased after single and multiple IV administrations. Following the final dose, geometric mean C max ranged from 218.9 to 970.9 µg/mL, and geometric mean AUC 0–inf ranged from 6634.8 to 17,779.1 h µg/mL across four dose levels. Ten subjects (41.7%) who received rhu‐pGSN reported a total of 13 adverse events (AEs), and one subject (12.5%) who received placebo reported an AE. All AEs were mild or moderate. No anti‐rhu‐pGSN antibodies were detected pre‐dose or at Day 28 post first dose. Overall, five IV rhu‐pGSN doses (up to 24 mg/kg daily) appeared safe and well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BioAegis Therapeutics, North Brunswick, NJ, USA.
Förderung
- BioAegis Therapeutics
Zitieren
APA
Liu, Y., Levinson, S. L., Kowalik, E., Pronchik, J., Kobzik, L., & DiNubile, M. J. (2026). A Phase 1, Single‐Center, Randomized, Double‐Blind, Placebo‐Controlled, Multiple‐Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu‐pGSN) Following Intravenous Administration to Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70094
Vancouver
Liu Y, Levinson SL, Kowalik E, Pronchik J, Kobzik L, DiNubile MJ. A Phase 1, Single‐Center, Randomized, Double‐Blind, Placebo‐Controlled, Multiple‐Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu‐pGSN) Following Intravenous Administration to Healthy Volunteers. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70094
BibTeX
@article{Liu2026,
author = {Liu, Yao and Levinson, Susan L and Kowalik, Edward and Pronchik, Jeremy and Kobzik, Lester and DiNubile, Mark J},
title = {A Phase 1, Single‐Center, Randomized, Double‐Blind, Placebo‐Controlled, Multiple‐Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu‐pGSN) Following Intravenous Administration to Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70094}
}
EUVIMED